Assessment of Serum Ischemia-modified albumin, Prolidase and Thiol-Disulphide Levels in Subjects With Breast Cancer

Dilli

et al. 2020

Kocatepe Tıp Dergisi

Tiyol/disülfit dengesi birçok hastalıkta önemli bir oksidatif belirteçtir. Kanserli olgularda biyo-belirteç olması yönünde çalışmalar yapılmaktadır. Bu çalışmanın amacı meme kanserli hastalarda tiyol-disülfid homeostazisi (Dinamik tiyol [-SH], disülfit [-S-S] ve total tiyol [TT] ) ile CA 15-3 (kanser antijeni 15-3) ve CEA [karsinoembriyojenik antijen], IMA[iskemik modifiye albümin], albümin arasındaki ilişkiyi araştırmak ve literatürde ilk kez yapılan sağlıklı kontrollerle karşılaştırmaktır. GEREÇ VE YÖNTEM: Hastalar kemoterapi altında çalışmaya katıldılar. Çalışma prospektif bir çalışmadır. Çalışmaya 39 kanserli hasta ve 41 sağlıklı toplamda 80 hasta dahil edildi. Çalışmamızda, tiyol-disülfid homeostazisindeki değişiklikler ve IMA, Albumin, CA 15-3 seviyelerine bakıldı. BULGULAR: Kontrol ile meme CA grupları arasında IMA, albumin ve CA-15-3 açısından istatiksel olarak anlamlı fark olduğu belirlendi (p<0.05). CA 15-3 in yüksek olduğu grupta SH/TT değerlerinde azalma, SS/TT değerlerinde artış görülmesine rağmen tiyol ve disülfid miktarlarında anlamlı bir değişiklik olmadı. Tiyol-disülfid parametreleri ile Meme Ca grubunda tümör biyo-belirteç değerleri arasında ilişki görülmedi. SONUÇ: Tiyol-disülfid homeostazisindeki değişikliklerin CA 15-3 ile etkileşmediği söylenebilir.

Section: Discussioncontrasting

confidence: 62%

The Association between Thiol-Disulphide Balance and CA-15-3 Levels in Patients with Breast Cancer

Dilli

et al. 2020

Kocatepe Tıp Dergisi

“…MPO is an endogenous metabolic/oxidative lysosomal enzyme secreted by neutrophils and monocytes, which can play a crucial role in tumor invasion by activating carcinogens into genotoxic intermediates and then enhancing xenogenic carcinogenicity (33). As reported, breast cancer patients have higher MPO levels, which may also reflect the oxidative stress imbalance of the disease (34). As to the role of oxidative stress in breast cancer, zapf et al (35) have stated that breast cancer patients have low levels of SOD and high levels of MPO, and simple chemotherapy would aggravate the oxidative stress levels of both.…”

Section: Discussionmentioning

confidence: 91%

Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER‑2‑positive breast cancer patients

Xiong

2020

Oncol Lett

Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. A total of 180 HER-2-positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), cellular immune indexes of T-lymphocyte subsets (CD4 + , CD8 + , CD4 + /CD8 +), and the oxidative stress indexes superoxide dismutase (SOD) and myeloperoxidase (MPO) were observed before and after treatment and were compared between both groups. Patients were followed up for 5 years, and the 5-year disease-free survival (DFS), as well as the overall survival (OS) were compared. Clinical efficacy and pathological efficacy in the RG were significantly higher than those in the CG, and the incidence rate of adverse reactions had no significant difference between the two groups. There was no significant difference in inflammatory factors, cellular immune indexes and oxidative stress indexes between the two groups before treatment. After treatment, the levels of IL-6, TNF-α, CD8 + and MPO in both groups were significantly reduced and were significantly lower in RG than those in CG. However, the levels of CD4 + , CD4 + /CD8 + and SOD in both groups were significantly increased after treatment and were significantly higher in RG than those in CG. The 5-year DFS and OS of the RG were significantly higher than those of the CG. In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress.

Ischemia-Modified Albumin: Origins and Clinical Implications

et al. 2021

Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool is located in the intravascular space and the remainder is found in the interstitial space. The content of this multifunctional protein in blood is about 60-65% of total plasma proteins. A decrease in its synthesis or changes of functional activity can destabilize oncotic blood pressure, cause a violation of transporting hormones, fatty acids, metals, and drugs. Albumin properties change under ischemic attacks associated with oxidative stress, production of reactive oxygen species, and acidosis. Under these conditions, ischemia-modified albumin (IMA) is generated that has a reduced metal-binding capacity, especially for transition metals, such as copper, nickel, and cobalt. The method of determining the cobalt-binding capability of HSA was initially proposed to evaluate IMA level and then licensed as an ACB test for routine clinical analysis for myocardial ischemia. Subsequent studies have shown the viability of the ACB test in diagnosing other diseases associated with the development of oxidative stress. This review examines recent data on IMA generation mechanisms, describes principles, advantages, and limitations of methods for evaluation of IMA levels, and provides detailed analysis of its use in diagnostic and monitoring therapeutic efficacy in different diseases.